PI3K/AKT/mTOR signaling in cancer
Moving in bioRxiv, Nature, Nature Communications, Blood, Cell Reports, Journal of Cell Biology and Nature Cell Biology.
- Moved, week to 23 Oct 2026
- 0
- Papers in 60 days
- 19
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in PI3K/AKT/mTOR signaling in cancer
Newest first · last 60 days
Roginolisib selectively inhibits PI3Kδ by stabilizing the C-terminal helix kα12, locking the enzyme in an inactive conformation.
- Open access
- 1 cites
Roginolisib demonstrates safety and achieves over 90% continuous PI3Kδ inhibition in patients with advanced cancers, including metastatic uveal melanoma, with median OS of 20.8 months.
- Open access
Loss of Lsp2 reduces TOP mRNA translation via 4E-BP, extending Drosophila lifespan independently of rapamycin, highlighting a new longevity pathway.
- 2 cites
Loss of TSC2 in neural progenitors causes cell-autonomous formation of reactive astrocytes with neurodegenerative features in tuberous sclerosis.
- Open access
Inhibition of Rag GTPases and mTORC1 in enterocytes increases intestinal stem cell activity via distinct pathways, with Rag GTPases affecting Mitf and mTORC1 acting independently.
Add PI3K/AKT/mTOR signaling in cancer as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6157
- medRxiv1716
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3